PHILADELPHIA—“My symptoms started in the final year of medical school, and at that stage I believed I was strong enough to fight my condition,” said Shung Ming Chiu, MD, in a poster presentation at ACR Convergence 2022. “Later, I realized that it’s not [about] fighting [but] rather accepting it and adapting to the new normal….
PHILADELPHIA—The term autoinflammatory syndrome was coined by Daniel L. Kastner, MD, PhD, National Institutes of Health (NIH), Bethesda, Md., not long after he discovered that mutations in the gene MEFV, which codes for the protein pyrin, are responsible for familial Mediterranean fever (FMF).1 Early on, the term was meant to signify monogenic conditions in which…
PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…
This session at ACR Convergence 2022, on Monday, Nov. 14, 2022, from 9–10 a.m. EST, will examine guidelines and current evidence regarding the management and outcomes of patients with ankylosing spondylitis (AS). Alexis Ogdie, MD, a rheumatologist and associate professor of Medicine at the University of Pennsylvania, Philadelphia, will present data to highlight the evolution…
With ~60 research abstracts on gout accepted for presentation at ACR Convergence 2022, filtering the noise to get to the key thoughts may be challenging. Lisa Stamp, MBChB, PhD, can help. A rheumatologist, professor of medicine and the associate dean of research at the University of Otago in Christchurch, New Zealand, she has extensively researched…
On Monday, Nov. 14, Michael Pillinger, MD, will moderate the session Gout Is an Autoinflammatory Metabolic Disease at ACR Convergence 2022. This session will address the autoinflammatory nature of gout and highlight it as an IL-1β-mediated diseases. Increasing knowledge on the inflammatory mechanisms of gout has implications for disease management. These engaging talks will review…
ACR Convergence 2022 will offer several opportunities to learn to leverage your expertise to support the rheumatology community, keep practices solvent and improve care of patients with rheumatic diseases. Look for sessions that explore why and how to pursue effective rheumatology advocacy and how to turn challenges into actionable results.
Pain is more than nociception, and pain management is more than medication. Delia Chiaramonte, MD, provided insights into how rheumatologists can help their patients ease and manage chronic pain.
In a small preliminary study, the novel MK2 inhibitor, CC-99677, was safe and well tolerated by healthy participants. With daily dosing, the agent sustained reductions of tumor necrosis factor alpha and other cytokines for 14 days.
With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.